Cargando…
Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open‐label study
A previous dose‐finding study has suggested that romiplostim is effective in patients with refractory aplastic anaemia (AA) and 10 µg/kg once weekly was recommended as a starting dose. In this Phase II/III, multicentre, open‐label study, romiplostim was administered subcutaneously at a fixed dose of...
Autores principales: | Jang, Jun Ho, Tomiyama, Yoshiaki, Miyazaki, Koji, Nagafuji, Koji, Usuki, Kensuke, Uoshima, Nobuhiko, Fujisaki, Tomoaki, Kosugi, Hiroshi, Matsumura, Itaru, Sasaki, Ko, Kizaki, Masahiro, Sawa, Masashi, Hidaka, Michihiro, Kobayashi, Naoki, Ichikawa, Satoshi, Yonemura, Yuji, Enokitani, Kouki, Matsuda, Akira, Ozawa, Keiya, Mitani, Kinuko, Lee, Jong Wook, Nakao, Shinji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821109/ https://www.ncbi.nlm.nih.gov/pubmed/33152120 http://dx.doi.org/10.1111/bjh.17190 |
Ejemplares similares
-
Distinctive and common features of moderate aplastic anaemia
por: Patel, Bhumika J., et al.
Publicado: (2020) -
Deficit of circulating CD19(+)CD24(hi)CD38(hi) regulatory B cells in severe aplastic anaemia
por: Zaimoku, Yoshitaka, et al.
Publicado: (2020) -
P827: EFFICACY AND SAFETY OF ROMIPLOSTIM ADDED TO IMMUNOSUPPRESSIVE THERAPY AS A FIRST-LINE TREATMENT IN PATIENTS WITH APLASTIC ANEMIA: A PHASE 2/3 CLINICAL TRIAL
por: Yamazaki, H., et al.
Publicado: (2022) -
Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia
por: Kumkhaek, Chutima, et al.
Publicado: (2008) -
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2007)